Cipher Pharmaceuticals Inc. (CPH.TO)

Cipher Pharmaceuticals Inc. (CPH.TO) — VMCI valuation read

CPH.TO screens at VMCI 57/100, a 7-point gap above the Healthcare sector median (50). For a mid-cap Cipher Pharmaceuticals Inc. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

CPH.TO has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: CPH.TO trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.2x leaves covenant headroom, which sets the rate-cycle exposure for Cipher Pharmaceuticals Inc..

CPH.TO rose 1.2% over the trailing 7 days, with a -0.6% read on a 30-day basis.